Read the conversation:

I'm here with Zack Bozinovski, the Managing Director of Wellnex Life. The company develops innovative pharmaceutical brands and intellectual property to improve health.  They are currently raising capital to grow their presence in the pharmaceutical market. Zack what are the three key points you would like the market to know about Wellnex?

What's important to understand about our company is the evolution of our company, uh, into a branded business, which has its own IP, which we can drive additional sales and revenue with in the market. Probably the second point is, and very importantly for us at the moment, is we're in the middle of a capital race for the acquisition of a company called PainAway

um, PainAway will deliver additional revenue profitability, but more importantly, we'll integrate seamlessly into the Wellnex business, um, to give us further growth and profitability moving forward. And I think the final point is, is that we're all about that continued innovation and IP development. Um, you know, we really spend a lot of time understanding what's happening overseas markets.

Talking to our retail partners here in both the grocery and pharmacy and then aligning on what um, direction these categories are going in and uh, ensuring that we develop products to align with that growth strategy. Thanks, Zack that was a great insight. To help investors understand Wellnex at a holistic level, can you please outline the strategy over the next 6 to 12 months?

Yeah, we, we're on a, um, on a very strong growth path with, uh, all of the products we've launched over the last 2 years. So over the last 2 years we've launched, uh, 6 brands, um, we've been involved in, uh, joint ventures. Uh, with companies like Chemist Warehouse and most importantly, and something that I'm very proud of the company is we have a global partnership with Halion, which was ex GSK for their Panadol Paracetamol brand, and they utilize our IP.

Um, for paracetamol in their brand and yeah, that is a really strong testament to what this company is about is the innovation, which I mentioned before, and the development and having major multinationals utilizing our products in their brands. I think the other part of where we're going is the acquisition of PainAway.

Uh, PainAway is an Australian owned, Australian made brand. It's number two in the topical, uh, health category. And we certainly believe by acquiring the brand and integrating into our business, um, we can certainly, uh, continue to drive revenue and growth, but also bring that new and unique innovation to the PainAway brand, uh, in our retailer partners.

On top of that, we're excited that we can take that brand into overseas markets, um, which is really important for us and also again, ensure that we continue that MPD development for our retailers, but also more importantly for consumers.  That paints a really exciting picture. Thanks for your time, Zack.

For more information about Wellnex and the investment opportunity, please click on the link in the description or reach out to us.

Investor Highlights:

• 100%-owned pharmaceutical brands - Mr. Bright, Wakey Wakey, Nighty Night, The Iron Company Pharmacy Own ranges in all major Pharmacy and Grocery retailers.
• IP-Licensing and contract manufacturing agreements with Haleon (formerly known as GlaxoSmithKline) to use Wellnex’s intellectual property (Dossier) for soft-gel analgesic product range in Australia and New Zealand, which recently has been expanded to the UK, Ireland and UAE.
• Two Joint Ventures with Chemist Warehouse for Australia’s first liquid paracetamol soft gel range under Wagner Health Liquigesics and the launch of Medicinal Cannabis products under the SAS-B market.
• Growing portfolio of Intellectual Property to support new innovative product launches.
• Growing revenue and increasing margins with revenue growing 51% in FY23 compared to FY22 and budgeted to grow a further 68% in FY24 putting the Company on pathway to profitability.